<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Feb. 9, 2018 (HealthDay News) — Good regional control can be achieved with up-front surgery and adjuvant therapy for patients with invasive nodal disease from oropharyngeal squamous cell carcinoma (SCC) related to human papillomavirus (HPV), according to a study published online Jan. 29 in Head & Neck<\/i>.<\/p>\n
Joseph Zenga, M.D., from Washington University in Saint Louis, and colleagues assessed oncologic outcomes among 72 patients with HPV-related oropharyngeal SCC requiring resection of major muscular or neurovascular tissue during neck dissection for invasive nodal disease.<\/p>\n
The researchers found that regional recurrences were seen in 6 percent of patients, and 17 percent experienced distant recurrences. Decreased disease-free survival was associated with advanced T classification, pathological node number \u22655, and omission of adjuvant therapy. However, adding adjuvant chemotherapy did not improve survival.<\/p>\n
“In patients with HPV-related oropharyngeal SCC requiring resection of major muscular or neurovascular tissue due to invasive nodal disease, up-front surgical management with adjuvant therapy results in excellent long-term regional control,” the authors write.<\/p>\n
Abstract<\/a><\/p>\n Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n